Literature DB >> 1732665

Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies.

R Bartl1, B Frisch, R Baumgart.   

Abstract

In a retrospective and prospective follow-up study from 1975 to 1991, bone marrow biopsies, aspirates and clinical features of 495 patients with MDS were investigated. Sections of undecalcified plastic embedded biopsies and smears of bone marrow aspirates were stained according to Giemsa. Bone marrows with MDS were characterized by three main categories of morphologic alterations: (1) cellular abnormalities, (2) architectural disorganization in the bone marrow and (3) stromal changes; the combined use of aspirates and trephine biopsies enabled a more reliable and accurate diagnosis of MDS than either one alone. The bone marrow findings fell into one of 7 subtypes, with the frequencies and median survivals in brackets: (1) MDS sideroblastic (19%, 62 months), (2) MDS megaloblastoid (13%, 56 months), (3) MDS proliferative (22%, 31 months), (4) MDS blastic (15%, 9 months), (5) MDS hypoplastic (15%, 26 months), (6) MDS fibrotic (6%, 29 months), and (7) MDS inflammatory (10%, 42 months). In follow-up studies patients with secondary MDS were excluded and the prognosis and subsequent evolution for each of the morphologic subtypes were evaluated. The conclusion is drawn that aspirates and trephine biopsies are complementary procedures and both are required for diagnosis, classification and decisions on current treatment modalities of patients with MDS.

Entities:  

Mesh:

Year:  1992        PMID: 1732665     DOI: 10.1016/0145-2126(92)90096-p

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  Hypocellular myelodysplastic syndromes: clinical and biological significance.

Authors:  Dragomir Marisavljevic; Vesna Cemerikic; Zoran Rolovic; Darinka Boskovic; Milica Colovic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Use of methyl methacrylate resin for embedding bone marrow trephine biopsy specimens.

Authors:  D Blythe; N M Hand; P Jackson; S L Barrans; R D Bradbury; A S Jack
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

Review 3.  Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis.

Authors:  Marc H G P Raaijmakers
Journal:  Int J Hematol       Date:  2012-01-06       Impact factor: 2.490

Review 4.  The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002).

Authors:  John M Bennett; Peter A Kouides; Stephen J Forman
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance.

Authors:  D Marisavljević; Z Rolović; V Cemerikić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

6.  Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes.

Authors:  J Thiele; I Hoffmann; H P Bertsch; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 7.  Diagnostics and Prognostication of Myelodysplastic Syndromes.

Authors:  Gina Zini
Journal:  Ann Lab Med       Date:  2017-11       Impact factor: 3.464

8.  Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.

Authors:  Silvia Maria Meira Magalhães; Lígia Niero-Melo; Maria de Lourdes Lopes Ferrari Chauffaille; Elvira Deolinda Rodrigues Pereira Velloso; Irene Lorand-Metze; Renata Buzzini; Wanderley Marques Bernardo
Journal:  Hematol Transfus Cell Ther       Date:  2018-07-02

9.  Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).

Authors:  Chi-Yuan Yao; Hsin-An Hou; Tzung-Yi Lin; Chien-Chin Lin; Wen-Chien Chou; Mei-Hsuan Tseng; Ying-Chieh Chiang; Ming-Chih Liu; Chia-Wen Liu; Yuan-Yeh Kuo; Shang-Ju Wu; Xiu-Wen Liao; Chien-Ting Lin; Bor-Shen Ko; Chien-Yuan Chen; Szu-Chun Hsu; Chi-Cheng Li; Shang-Yi Huang; Ming Yao; Jih-Luh Tang; Woei Tsay; Chieh-Yu Liu; Hwei-Fang Tien
Journal:  Oncotarget       Date:  2016-09-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.